Markets
Macbeth at the Leeds Playhouse
Macbeth and Lady Macbeth (Photo by Danny Lawson/Getty Images)

It’s a Macbeth market: full of sound and fury, signifying nothing

Volatility markets and credit markets are at odds. And the stock market disagrees with itself.

The good news: the wounds inflicted on global markets this week look a lot more technical than fundamental. The bad news: the wounds inflicted on global markets this week look a lot more technical than fundamental – so far.

Volatility markets and credit markets – which typically behave the same way in times of financial stress – are completely at odds. And in the equity market, investors can’t make up their minds whether to focus on rotating out of megacap tech into more cyclical parts of the market, or seeking safety in defensive sectors as recession fears creep higher.

If the dust from recent mechanical, panic-induced selling dissipates, the backdrop could look fairly benign before long. The S&P 500’s earnings expectations are still improving, profit results are largely beating expectations, and investors may grow more confident that easing from the Federal Reserve will stabilize the labor market and the economy before long.

But it’s also easy to take off the rose-colored glasses and see a more perverse future. If the outlook for the US economy continues to soften, cyclical parts of the market might have a lot more downside – just as investors are beginning to question the ROI on AI spending.

The challenge for investors in the coming days and weeks will be the search for cohesion in a Macbeth market, where the price action has been full of sound and fury, signifying nothing.

With the S&P 500’s fear gauge hitting levels only seen during the 2008 financial crisis and the 2020 pandemic, the signal from volatility markets is that the world is on fire. But the credit market continues to say it’s fine. The surge in the VIX Index on Monday was accompanied by a relatively tepid widening in credit spreads.

More important than the one-day moves are the absolute levels these metrics finished at during Monday’s rout. The VIX ended the session at its 96th percentile relative to history (i.e., it’s only been higher on 4% of sessions going back to August 2000). High-yield credit spreads are in their 33rd percentile – in other words, investors are usually much more worried about the potential for a wave of corporate defaults than they are now.

For better or for worse, the US stock market remains tethered to Japanese assets right now. When US stocks have a stronger connection with Japanese assets than with US credit markets, your eyebrows should go up: this is definitely not normal.

Speaking of abnormal, we have the completely muddled internals of the US equity market.

On the one hand, the Financial Select Sector, Industrial Select Sector, and SPDR S&P Regional Banking ETFs are all closer to their 52-week highs than the Nasdaq 100. This is a market that still bears a lot of the hallmarks of the “rotation” narrative that was in full swing in early to mid July, when a narrow, AI-dominated market shifted into one with more breadth, with small caps and more cyclical stocks performing well. 

This isn’t what markets trade like when recession worries are ascending.

“If company fundamentals are in decent shape, this begets the question as to whether valuations have to now re-rate lower because a recession is more obviously on the horizon today than it was in April,” writes Michael Purves, founder of Tallbacken Capital Advisors. “Our view is this question will haunt cyclicals and the ‘rotation equities’ much more so than it will haunt the big tech indices.”

That being said, tech companies are the most expensive part of a richly valued market, and the bar for them to attract more love from investors seems to be high. With six of the so-called Magnificent Seven having reported results so far this season (all save Nvidia), the average member has fallen 3.6% the session after releasing their quarterly update.

On the other hand, defensive, rate-sensitive sectors are trouncing the US stock market as a whole, something that is generally seen when risk aversion and fears about the economic outlook are high.

Utilities, for instance, have outperformed the S&P 500 by more than 9% over the past two weeks. That’s 99th percentile outperformance. The only times we’ve seen this defensive sector do even better than the benchmark US stock gauge has been during bear markets (March 2022 and the 2008 financial crisis) or relatively deep equity market drawdowns (2018, early 2016).

And investors seem to doubt that consumer-centric parts of the equity market will be able to maintain their recent operating performance – in large part because these companies sound circumspect, if not gloomy, about the road ahead.

“Many clients have fixated on downbeat commentary about the US consumer from select corporates,” writes Goldman Sachs chief US equity strategist David Kostin.

Kostin flagged how consumer discretionary that have exceeded expectations on quarterly profits outperformed the S&P 500 by a paltry 0.2% the following session. Normally, stocks that beat earnings estimates go on to best the benchmark US stock gauge by 1%.

It’s going to take time to wrestle through these competing narratives and mixed messages.

“Our sense is the market will stay violently flat – little direction at the index level, but lots of internal realized vol – until the breadth of data can allay recession fears,” writes Dennis DeBusschere, chief market strategist and founder of 22V Research. “We’d be surprised if the market melted down because of the one payroll reading.”

Stepping back, it’s a complete mess out there. And a market that doesn’t make too much sense is probably a market you shouldn’t try to make too much sense of.

More Markets

See all Markets
markets

CrowdStrike beats on Q3 revenue and earnings

CrowdStrike eked out beats on both earnings and revenue for the third quarter, while also raising its full-year guidance.

The cybersecurity company reported earnings of $0.96 per share, beating analysts’ consensus estimate of $0.94 per share.

The company saw $1.23 billion in sales for the quarter, up 22% year on year, beating analysts’ expectation of $1.21 billion in sales. The company reported a net loss of about $34 million.

Subscription revenue was $1.17 billion, up 21% year on year.

Shares were little changed in after-hours trading. The stock is up nearly 50% since the start of the year.

The company’s annual recurring revenue reached $4.92 billion as of October 31, up 23% year on year. The analyst consensus was $4.895 billion.

The company raised its fiscal year 2026 guidance for revenue to between $4.8 billion to $4.81 billion (previously $4.75 billion to $4.81 billion), and upped its outlook for adjusted earnings per share to a range of $3.70 to $3.72 (previously $3.60 to $3.72).

Burt Podbere, CrowdStrike’s CFO, wrote in the press release:

“We delivered outstanding third quarter results, exceeding expectations across all guided metrics. Total revenue growth accelerated to 22% year-over-year, and we delivered record cash flow from operations of $398 million and record Q3 free cash flow of $296 million. We are capitalizing on the AI-driven demand environment as customers consolidate on the Falcon platform, driving our pipeline to an all-time high.”

markets

Marvell Technology soars after CEO targets $10 billion in revenues next year

Despite Marvell Technology initially falling in after-hours trading after the chip company posted Q3 results modestly ahead of estimates and Q4 guidance in line with expectations, it’s now turned those losses into massive gains thanks to positive commentary on next year’s sales outlook. Shares are up almost 10% as of 5:20 a.m. ET.

On the earnings call, CEO Matt Murphy said that sales could eclipse $10 billion in its upcoming fiscal year, while analysts had penciled in a forecast below $9.5 billion.

That solid anticipated pick-up in sales is being driven by Marvell’s custom chip division, where Murphy touted recent customer wins including an “emerging hyperscaler.”

“We expect our custom business, roughly a quarter of our overall data center revenue, to grow by at least 20% next year,” he said.

While custom chips sales have been a relatively lumpy line item for Marvell, Murphy doesn’t think that will be the case going forward, saying that there won’t be any more “air pockets.”

The Q3 results:

  • Net revenue: $2.075 billion (compared to estimates for $2.06 billion)

  • Adjusted earnings per share: $0.76 (estimate: $0.74)

For Q4, management offered guidance for net revenues to come in at $2.2 billion (plus or minus 5%) with adjusted EPS of $0.79 (plus or minus $0.05). That’s virtually bang in line with Wall Street’s call for $2.19 billion and $0.79, respectively.

Along with these results, Marvell announced plans to buy Celestial AI, a company that uses light to move data between chips, for at least $3.25 billion in cash and stock. The purchase price could go up by as much as $2.25 billion if Celestial’s cumulative revenues reach at least $2 billion by the end of Marvell’s fiscal 2029 (roughly speaking, calendar year 2028).

The chip stock has been on a solid run recently, thanks in large part to a wave of investor enthusiasm over custom chips spurred by the launch of Google’s Gemini 3. Marvell works with Amazon as a codesigning partner for its custom chips, including providing connectivity infrastructure for the Trainium3 model, which was publicly launched on Tuesday.

That being said, Marvell has been one of the worst chip stocks this year, and is still down around 7.5% for the year so far.

markets

Morgan Stanley upgrades Tempus AI to “overweight”

Morgan Stanley analysts gave Tempus AI an “overweight” rating — essentially a “buy” — and a raised their price target to $85 from $80, writing in a note published late Monday that despite being “a relatively new player, the company has already established itself as one of the top providers of precision oncology testing.”

As part of their reasoning, analysts spotlighted faster-than-expected growth in Tempus’ hereditary cancer risk-testing business, which it acquired through the purchase of Ambry Genetics in a deal that closed earlier this year.

Morgan Stanley also suggested there could be upside in Tempus’ relatively small data and services unit, which sells de-identified patient data pulled from its testing archive for use in pharmaceutical drug trials and other applications.

Despite being consistently unprofitable since its IPO last year, Tempus has been winning over Wall Street analysts.

Of the 17 covering the stock, 10 have buy ratings — or their equivalent — on Tempus, up from six in June.

Tempus has seen its share price more than double this year.

Wall Street 2026 outlook and S&P 500 forecasts (binoculars)

Wall Street has great expectations for the next year in the stock market

Stock watchers are pretty bullish about the coming year — as they typically are — with eyes on the Fed and whether the AI boom will still have legs. BofA is a little skeptical.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.